RESUMO
Alzheimer's disease (AD) is a neurodegenerative disease that affects cognition and behavior. The neuroinflammatory response in the brain is an important pathological characteristic in AD. In this study, we investigated the neuroprotective effects of 1-Methylnicotinamide (MNA), known as the main metabolite of nicotinamide, on reducing lipopolysaccharide (LPS)-induced cognitive deficits via targeting neuroinflammation and neuronal apoptosis. We found that the mice treated with LPS exhibited cognitive deficits in the novel object recognition, Morris water maze and Y-maze avoidance tests. However, intragastric administration of MNA (100 or 200â¯mg/kg) for 3â¯weeks significantly attenuated LPS-induced cognitive deficits in mice. Importantly, MNA treatment suppressed the protein expression of nuclear factor-kappa B p65 (NF-κB p65), pro-inflammatory cytokines (TNF-α, IL-6) and decreased the activation of microglia and astrocytes in the hippocampus and frontal cortex of LPS-induced mice. In addition, MNA treatment suppressed neuronal apoptosis by reducing the number of TUNEL-positive cells, caspase-3 activation and increasing the level of Bcl-2/Bax ratio in the hippocampus and frontal cortex. These findings indicate that MNA could be a potential neuroprotective drug in neurodegenerative diseases such as AD.
Assuntos
Anti-Inflamatórios/uso terapêutico , Transtornos Cognitivos/tratamento farmacológico , Transtornos da Memória/tratamento farmacológico , Fármacos Neuroprotetores/uso terapêutico , Niacinamida/análogos & derivados , Animais , Anti-Inflamatórios/farmacologia , Apoptose/efeitos dos fármacos , Transtornos Cognitivos/induzido quimicamente , Transtornos Cognitivos/imunologia , Lobo Frontal/efeitos dos fármacos , Hipocampo/efeitos dos fármacos , Interleucina-6/imunologia , Lipopolissacarídeos , Masculino , Transtornos da Memória/induzido quimicamente , Transtornos da Memória/imunologia , Camundongos Endogâmicos ICR , Neurônios/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Niacinamida/farmacologia , Niacinamida/uso terapêutico , Fator de Transcrição RelA/imunologia , Fator de Necrose Tumoral alfa/imunologiaRESUMO
Aging is spontaneous and inevitable processes that lead to changes in biological systems. The present paper was designed to investigate the anti-aging roles of chick embryo (CE) and nutrient mixture (NM) in aging rats. Aging was induced by administration of D-galactose (D-gal, 500 mg/kg/day for 90 days). CE and NM were administered to aging rats through different dose gavage once a day. Cognitive function assessment was performed using the Morris water maze test. At the end of experiment, serum and tissues were collected for immunity and antioxidation function. The organs and tissues were excised for histological study. The results demonstrated that CE plus NM was superior treatment to improve the histopathologic changes and reverse learning and memory impairment of the aging rats. CE plus NM also increased the spleen and thymus index as well as splenocyte proliferation, and reversed inflammatory cytokine levels. In addition, the biochemical index showed that CE plus NM could improve the antioxidant enzyme activity of the aging rats, decrease lipofuscin (LF) and glutamate content. CE plus NM also inhibited the activation of TLR4/NF-κB pathway stimulated by LPS in splenic B lymphocytes. Overall, these results seem to be implying that CE plus NM was used as potentially natural supplement or functional food for preventing aging.
Assuntos
Envelhecimento/imunologia , Transtornos Cognitivos/induzido quimicamente , Transtornos Cognitivos/imunologia , Nutrientes/farmacologia , Estresse Oxidativo , Envelhecimento/patologia , Animais , Antioxidantes/metabolismo , Linfócitos B/efeitos dos fármacos , Peso Corporal , Encéfalo/efeitos dos fármacos , Encéfalo/enzimologia , Embrião de Galinha , Transtornos Cognitivos/patologia , Modelos Animais de Doenças , Galactose , Ácido Glutâmico/metabolismo , Peptídeos e Proteínas de Sinalização Intercelular/análise , Interleucina-2/análise , Interleucina-4/análise , Lipopolissacarídeos , Fígado/efeitos dos fármacos , Fígado/enzimologia , Masculino , Aprendizagem em Labirinto/efeitos dos fármacos , Memória/efeitos dos fármacos , NF-kappa B/metabolismo , Óvulo/química , Estresse Oxidativo/efeitos dos fármacos , Ratos Sprague-Dawley , Baço/patologia , Fator de Células-Tronco/análise , Receptor 4 Toll-Like/metabolismoRESUMO
Beta-amyloid (Aß) deposition and neuroinflammation are involved in Alzheimer's disease (AD)-type neurodegeneration with cognitive deficits. Phosphodiesterase-5 (PDE5) inhibitors have recently been studied as a potential target for cognitive enhancement by reducing inflammatory responses and Aß levels. The present study was designed to investigate the effects of icariside II (ICS II), a novel PDE5 inhibitor derived from the traditional Chinese herb Epimedium brevicornum, on cognitive deficits, Aß levels and neuroinflammation induced by intracerebroventricular-streptozotocin (ICV-STZ) in rats. The results demonstrated that ICV-STZ exhibited cognitive deficits and neuronal morphological damage, along with Aß increase and neuroinflammation in the rat hippocampus. ICS II improved cognitive deficits, attenuated neuronal death, and decreased the levels of Aß1-40, Aß1-42 and PDE5 in the hippocampus of STZ rats. Furthermore, administration of ICS II at the dose of 10mg/kg for 21days significantly suppressed the expression of beta-amyloid precursor protein (APP), beta-secretase1 (BACE1) and increased the expressions of neprilysin (NEP) together with inhibited interleukin-1ß (IL-1ß), tumor necrosis factor (TNF)-α, cyclooxygenase-2 (COX-2) and transforming growth factor-ß1 (TGF-ß1) levels. In addition, ICS II exerted a beneficial effect on inhibition of IκB-α degradation and NF-κB activation induced by STZ. Taken together, the present study demonstrated that ICS II was a potential therapeutic agent for AD treatment.
Assuntos
Transtornos Cognitivos/tratamento farmacológico , Flavonoides/farmacologia , Hipocampo/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Nootrópicos/farmacologia , Animais , Transtornos Cognitivos/imunologia , Transtornos Cognitivos/patologia , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Hipocampo/imunologia , Hipocampo/patologia , Masculino , Aprendizagem em Labirinto/efeitos dos fármacos , Aprendizagem em Labirinto/fisiologia , Neurônios/efeitos dos fármacos , Neurônios/imunologia , Neurônios/patologia , Inibidores da Fosfodiesterase 5/farmacologia , Distribuição Aleatória , Ratos Sprague-Dawley , EstreptozocinaRESUMO
The study aimed to assess the effect of the polypeptide Y complex (Yolkin), isolated from chicken egg yolk, on behavioural and cognitive functions. It also aimed to compare this activity with colostrum-derived substances (Colostrinin, Coloco), which have a confirmed impact on learning and memory. In the study, the effect of Yolkin, administered to rats of different ages, who performed various tasks involving spatial and episodic memory, motor functions and exploratory behavior, was assessed. The experiment was carried out in rats which were 6 and 12 months old. Two different doses of the studied specimens based on previous comparative studies and two different routes of administration (oral and retroperitoneal) were used. A series of behavioural tests were carried out, including an open field test, a novel object recognition test and a Morris water maze. They were used to evaluate the impact of the studied specimen on improving locomotor function and exploratory behaviour, preventing their decline and assess the functioning of episodic and spatial memory in aging rats. The administration of Yolkin gave distinct effects compared to colostrum-derived substances, although confirmed its suggested pro-cognitive action. Therefore, it may be used to enhance cognitive functions and inhibit the progression of dementia in the course of neurodegenerative disorders.
Assuntos
Proteínas Aviárias/administração & dosagem , Proteínas Aviárias/imunologia , Transtornos Cognitivos/imunologia , Cognição/fisiologia , Colostro/imunologia , Proteínas do Ovo/administração & dosagem , Proteínas do Ovo/imunologia , Gema de Ovo/imunologia , Envelhecimento , Animais , Peso Corporal , Galinhas , Sistema Imunitário , Imunomodulação/imunologia , Masculino , Aprendizagem em Labirinto , Memória , Ratos , Ratos WistarRESUMO
Age-associated cognitive decline and dementia are conditions in which there is deterioration in memory, thinking, and behavior, with profound effects on the ability to perform everyday activities and well-being. Even if dementia mainly affects older persons, it is not a normal part of aging. Alzheimer's disease accounts for 60-75% of dementia cases. The number of persons affected will increase in the next decades in parallel with aging of the world population. Hence, unless some approach is found to reduce age-related deterioration of cognitive functions, health care costs will continue to rise exponentially. There is a wealth of epidemiological evidence supporting a relationship between diet and Alzheimer's disease, and suggesting that the risk of cognitive decline may be reduced by dietary interventions. It has been proposed that adopting a healthy diet and lifestyle that improves cardiovascular function may help delaying the onset of Alzheimer's disease due to its potential association with vascular disease. Several nutrients, dietary components, supplements and dietary patterns have been reported in relation to their association with cognition and with the development of cognitive decline and Alzheimer's disease. The possible effect of diet on the prevention of dementia is of tremendous scientific and general interest, because hitherto there is no definitive evidence of any effective pharmacological treatment for dementia. The aim of this review is to evaluate the evidence for the effects of some dietary components, supplements, and dietary patterns as neuroprotective, with potential to delay cognitive decline and the onset of dementia.
Assuntos
Doença de Alzheimer/dietoterapia , Transtornos Cognitivos/prevenção & controle , Ácidos Graxos Ômega-3/uso terapêutico , Preparações de Plantas/uso terapêutico , Vitaminas/uso terapêutico , Doença de Alzheimer/complicações , Doença de Alzheimer/imunologia , Transtornos Cognitivos/etiologia , Transtornos Cognitivos/imunologia , Dietoterapia/métodos , Suplementos Nutricionais , Ácidos Graxos Ômega-3/administração & dosagem , Humanos , Preparações de Plantas/administração & dosagem , Resultado do Tratamento , Vitaminas/administração & dosagemRESUMO
Neuroinflammatory processes are known to contribute to the cascade of events culminating in the neuronal damage that underpins neurodegenerative disorders such as Parkinson's and Alzheimer's disease. With the ageing population and increased cases of neurodegenerative diseases, there is a crucial need for the development of new strategies capable to prevent, delay the onset or treat brain dysfunction and associated cognitive decline. Growing evidence sheds light on the use of dietary polyphenols and n-3 long chain polyunsaturated fatty acids to improve cognitive performance and reduce the neuroinflammatory and oxidative stress responses occurring with age and neurodegenerative pathologies. This review will summarise the most recent information related to the impact and mechanisms underlying the neuroinflammatory processes in neurodegenerative disorders. We will also detail the current evidence indicating that flavonoids and n-3 polyunsaturated fatty acids are strong candidates in preventing neuroinflammation and modulating age-related memory decline, and we will describe the potential mechanisms of action underlying their neuroprotective effects. As such, these dietary bioactives represent important precursor molecules in the quest to develop a new generation of drugs capable of counteracting neuroinflammation and neurodegenerative diseases.
Assuntos
Transtornos Cognitivos/tratamento farmacológico , Ácidos Graxos Ômega-3/administração & dosagem , Flavonoides/administração & dosagem , Doenças Neurodegenerativas/tratamento farmacológico , Fármacos Neuroprotetores/administração & dosagem , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/imunologia , Encéfalo/metabolismo , Transtornos Cognitivos/imunologia , Transtornos Cognitivos/metabolismo , Humanos , Mediadores da Inflamação/antagonistas & inibidores , Mediadores da Inflamação/imunologia , Mediadores da Inflamação/metabolismo , Microglia/efeitos dos fármacos , Microglia/imunologia , Microglia/metabolismo , Doenças Neurodegenerativas/imunologia , Doenças Neurodegenerativas/metabolismoRESUMO
Neurosarcoidosis is a rare central nervous system manifestation of sarcoidosis. T cell, T-helper cell and macrophage activation via the major histocompatibility complex (MHC) II-mediated pathway causes this disease. Little is known about the possible cognitive disturbances in this disease as most reported instances are case studies. Here, we provide the first in-depth analysis of psychomotor functions in a sample of 30 neurosarcoidosis patients. We investigated action control processes using a paradigm that is able to examine how different tasks are cascaded to achieve the task goal. We integrated electrophysiological (EEG) data with behavioural and neuroimmunological data. Our results show that there was no general cognitive decline in patients with neurosarcoidosis. Patients only presented deficits when two response options have to be prioritized. Patients apply an inefficient processing strategy where they try to processes different response options in parallel. The electrophysiological data show that the deficits are due to dysfunctions at the response selection stage. Behavioural and neurophysiological changes are predictable on the basis of soluble interleukin 2 receptor serum concentrations. The results show that neurosarcoidosis is not associated with nonspecific changes in cognitive functions but does lead to specific alterations in cognitive control that are strongly dependent on immunological parameters.
Assuntos
Doenças do Sistema Nervoso Central/metabolismo , Transtornos Cognitivos/etiologia , Citocinas/fisiologia , Função Executiva/fisiologia , Desempenho Psicomotor/fisiologia , Receptores de Interleucina-2/sangue , Sarcoidose/metabolismo , Estimulação Acústica , Adulto , Idoso , Atenção , Biomarcadores , Estudos de Casos e Controles , Doenças do Sistema Nervoso Central/diagnóstico , Doenças do Sistema Nervoso Central/imunologia , Doenças do Sistema Nervoso Central/psicologia , Transtornos Cognitivos/imunologia , Transtornos Cognitivos/metabolismo , Transtornos Cognitivos/psicologia , Tomada de Decisões/fisiologia , Eletroencefalografia , Feminino , Humanos , Julgamento/fisiologia , Masculino , Pessoa de Meia-Idade , Testes Neuropsicológicos , Estimulação Luminosa , Sarcoidose/diagnóstico , Sarcoidose/imunologia , Sarcoidose/psicologiaRESUMO
Obesity is a growing problem worldwide and is associated with a range of comorbidities, including cognitive dysfunction. In this review we will address the evidence that obesity and high fat feeding can lead to cognitive dysfunction. We will also examine the idea that obesity-associated systemic inflammation leads to inflammation within the brain, particularly the hypothalamus, and that this is partially responsible for these negative cognitive outcomes. Thus, obesity, and high fat feeding, lead to systemic inflammation and excess circulating free fatty acids. Circulating cytokines, free fatty acids and immune cells reach the brain at the level of the hypothalamus and initiate local inflammation, including microglial proliferation. This local inflammation likely causes synaptic remodeling and neurodegeneration within the hypothalamus, altering internal hypothalamic circuitry and hypothalamic outputs to other brain regions. The result is disruption to cognitive function mediated by regions such as hippocampus, amygdala, and reward-processing centers. Central inflammation is also likely to affect these regions directly. Thus, central inflammation in obesity leads not just to disruption of hypothalamic satiety signals and perpetuation of overeating, but also to negative outcomes on cognition.
Assuntos
Transtornos Cognitivos/etiologia , Cognição/fisiologia , Hipotálamo/imunologia , Inflamação/complicações , Obesidade/complicações , Animais , Transtornos Cognitivos/imunologia , Transtornos Cognitivos/metabolismo , Dieta Hiperlipídica , Humanos , Hipotálamo/metabolismo , Inflamação/imunologia , Inflamação/metabolismo , Obesidade/imunologia , Obesidade/metabolismoRESUMO
Physical activity (PA) is emerging as a safe and effective tool in the prevention and treatment of psychiatric disorders. PA subtypes include aerobic, resistance, flexibility, neuromotor (involving balance, agility and co-ordination), mind-body (e.g. tai chi, qi gong and yoga) and mixed type trainings. Evidence from clinical trials suggests that PA subtypes can have positive clinical effects, however the effects on the symptomatology may vary according to the PA subtype. It therefore stands to reason that various PA subtypes may modulate the immune system and neuroplastic processes differently. This systematic review aims to assess the immunomodulatory and neuroplastic profiles of various PA subtypes, particularly in unipolar depression and age-related cognitive decline (ARCD). The literature suggests several unique immunomodulatory and neuroplastic profiles for PA subtypes (i.e. resistance, aerobic and mind-body) in depression and ARCD. In depression, levels of various cytokines at baseline may predict treatment response to subtypes of PA and pharmacological agents. The pro-neuroplastic effects of resistance and aerobic PA in ARCD may differ due to variances in neurotrophin profiles. At this stage of literature in the field, it is difficult to draw firm conclusions on the specific immunomodulatory and neuroplastic pathways involved in these PA subtypes given of the small number of comparative studies and methodological heterogeneity between studies (e.g. study population age and illness severity, as well as duration and intensity of PA intervention). This important field requires well-designed, high-quality comparative studies to better describe unique immunomodulatory and neuroplastic profiles.
Assuntos
Transtornos Cognitivos/imunologia , Transtornos Cognitivos/terapia , Transtorno Depressivo/imunologia , Transtorno Depressivo/terapia , Terapia por Exercício , Plasticidade Neuronal/imunologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Citocinas/metabolismo , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Crescimento Neural/metabolismo , Adulto JovemAssuntos
Anticorpos Monoclonais Murinos/uso terapêutico , Antirreumáticos/uso terapêutico , Arteterapia/métodos , Doenças Autoimunes do Sistema Nervoso/imunologia , Doenças Autoimunes do Sistema Nervoso/reabilitação , Encefalite/imunologia , Encefalite/reabilitação , Imunização Passiva , Metilprednisolona/uso terapêutico , Transtornos Neurocognitivos/imunologia , Transtornos Neurocognitivos/reabilitação , Receptores de N-Metil-D-Aspartato/imunologia , Adolescente , Transtornos Cognitivos/imunologia , Transtornos Cognitivos/reabilitação , Quimioterapia Combinada , Feminino , Humanos , Entrevista Psiquiátrica Padronizada , Escalas de Graduação Psiquiátrica , RituximabRESUMO
Recently, reports have suggested grouping different autoimmune conditions that are triggered by external stimuli as a single syndrome called autoimmune syndrome induced by adjuvants (ASIA). This syndrome is characterized by the appearance of myalgia, myositis, muscle weakness, arthralgia, arthritis, chronic fatigue, sleep disturbances, cognitive impairment and memory loss, and the possible emergence of a demyelinating autoimmune disease caused by systemic exposure after vaccines and adjuvants. As there are no markers for ASIA, the authors intend to present ASIA, or Shoenfeld's syndrome, as an autoimmune syndrome induced by adjuvants.
Assuntos
Adjuvantes Farmacêuticos/efeitos adversos , Doenças Autoimunes/induzido quimicamente , Doenças Autoimunes/imunologia , Cadeias HLA-DRB1/imunologia , Vacinas/efeitos adversos , Artralgia/imunologia , Artrite/imunologia , Doenças Autoimunes/epidemiologia , Biomarcadores/metabolismo , Transtornos Cognitivos/imunologia , Fadiga/imunologia , Humanos , Inflamação/imunologia , Transtornos da Memória/imunologia , Debilidade Muscular/imunologia , Mialgia/imunologia , Miosite/imunologia , Romênia/epidemiologia , Silicones/efeitos adversos , Transtornos do Sono-Vigília/imunologia , SíndromeRESUMO
OBJECTIVE: Systemic lupus erythematosus (SLE) presents with psychiatric symptoms in most patients that often remain undiagnosed and untreated. This study evaluates the prevalence of psychiatric symptoms in SLE on the basis of clinical trials that fulfilled diagnostic criteria specified by the American College of Rheumatology (ACR). Current hypotheses explaining the pathogenesis of psychiatric symptoms of lupus are reviewed to gain new insights into the neuroimmune pathogenesis of other psychiatric disorders. DATA SOURCE: A MEDLINE search of the literature (English language only) from April 1999 to August 2011 was performed using the search terms lupus and psychiatric to identify studies of neuropsychiatric SLE. STUDY SELECTION: Of 163 publications, 18 clinical studies were selected that focused on psychiatric symptoms, had a sample size of at least 20, and included patients of any age or gender as long as they fulfilled ACR criteria for neuropsychiatric SLE. DATA EXTRACTION: The following data were extracted: author name, year of publication, psychiatric diagnostic method, total number of patients with SLE, and percentage of patients with individual psychiatric diagnoses. The point prevalence of psychiatric symptoms was calculated for neuropsychiatric SLE diagnoses in every study included. RESULTS: Psychiatric symptoms are present in the majority of patients with SLE. Depression (in up to 39% of patients) and cognitive dysfunction (up to 80%) are the most common psychiatric manifestations. Genetic and environmental factors (eg, ultraviolet light, retroviruses, and medications) may play a role in the pathogenesis. In addition, the patient's reaction to the illness may result in anxiety (up to 24%) and depression. Currently known biomarkers are nonspecific for neuropsychiatric SLE and indicate inflammation, microglial activation, ischemia, oxidative stress, mitochondrial dysfunction, and blood-brain barrier dysfunction. CONCLUSIONS: Identification of lupus-specific biomarkers of psychiatric symptoms is a high priority. Our current diagnostic assessment methods need improvement. Development of evidence-based guidelines is needed to improve diagnosis, prevention, and treatment of disabling psychiatric complications in lupus.
Assuntos
Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/psicologia , Transtornos Neurocognitivos/psicologia , Anticorpos Antinucleares/sangue , Transtorno do Deficit de Atenção com Hiperatividade/diagnóstico , Transtorno do Deficit de Atenção com Hiperatividade/epidemiologia , Transtorno do Deficit de Atenção com Hiperatividade/imunologia , Transtorno do Deficit de Atenção com Hiperatividade/psicologia , Biomarcadores/sangue , Transtorno Bipolar/diagnóstico , Transtorno Bipolar/epidemiologia , Transtorno Bipolar/imunologia , Transtorno Bipolar/psicologia , Transtornos Cognitivos/diagnóstico , Transtornos Cognitivos/epidemiologia , Transtornos Cognitivos/imunologia , Transtornos Cognitivos/psicologia , Estudos Transversais , Transtorno Depressivo Maior/diagnóstico , Transtorno Depressivo Maior/epidemiologia , Transtorno Depressivo Maior/psicologia , Diagnóstico Precoce , Humanos , Lúpus Eritematoso Sistêmico/epidemiologia , Lúpus Eritematoso Sistêmico/imunologia , Transtornos Neurocognitivos/diagnóstico , Transtornos Neurocognitivos/epidemiologia , Transtornos Neurocognitivos/imunologia , Psiconeuroimunologia , Transtornos Psicóticos/diagnóstico , Transtornos Psicóticos/epidemiologia , Transtornos Psicóticos/imunologia , Transtornos Psicóticos/psicologia , Fatores de RiscoRESUMO
Spatial learning and memory are impaired in diabetic animals. The interaction of advanced glycation end products (AGEs) with the receptor of AGEs (RAGE), resulting in the activation of nuclear factor-κB (NF-κB), plays an important role in pathways leading to the cytotoxic effects to neurons. Danshensu, a compound from Salvia miltiorrhiza Bunge, has neuroprotective effects. This study aimed to investigate the role of AGE-mediated neuroinflammation in learning and memory deficits and the effect of Danshensu on the cognitive decline in diabetic mice. C57BL/6 mice were injected intraperitoneally with streptozotocin. Sodium Danshensu (sodium salt of Danshensu) was administered at a dose of 15, 30, or 60 mg/kg for 12 weeks. The results showed that diabetes caused impairment in acquisition and retrieval processes, as demonstrated by performance in the Morris water maze test. Danshensu not only reduced the mean escape latency but also increased the percentage of time spent in the target quadrant. Western blot analysis revealed that there was a significant increase in the expression of RAGE, p-p38, and COX-2, and the NF-κB activation. Danshensu partly blocked the expression of RAGE, p-p38, and COX-2, and NF-κB activation, and inhibited the increase of TNF-α, IL-6, and PGE2. However, Danshensu did not affect body weight and the levels of blood glucose, glycosylated hemoglobin, insulin, and AGEs. These findings demonstrate that AGE-mediated neuroinflammation plays an important role in learning and memory deficits in diabetic mice and that Danshensu may provide a potential alternative for the prevention of cognitive impairment associated with diabetes by attenuating AGE-mediated neuroinflammation.